Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.600
+0.070 (4.58%)
At close: Jul 2, 2026, 4:00 PM EDT
1.610
+0.010 (0.63%)
After-hours: Jul 2, 2026, 7:54 PM EDT
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,874,582
Market Cap
6.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2024 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Sep 30, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Dec 31, 2021 | 3 | 0 | - | 3 | 0 |
| Mar 31, 2021 | 3 | - | - | 2 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| NextCure | 40 |
| Bolt Biotherapeutics | 23 |
| AIM ImmunoTech | 21 |
| TransCode Therapeutics | 12 |
| CNS Pharmaceuticals | 8 |
| Immuron | 7 |
| Silo Pharma | 3 |
ACXP News
- 18 days ago - Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - PRNewsWire
- 7 weeks ago - Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Acurx Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Acurx Pharmaceuticals Earnings release: Q1 2026 - Filings
- 7 weeks ago - Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update - PRNewsWire
- 2 months ago - Acurx files to sell 1.65M shares of common stock for holders - TheFly
- 2 months ago - Acurx files to sell 1.3M shares of common stock for holders - TheFly
- 2 months ago - Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 - PRNewsWire